Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | PDE2A | O00408 | 4/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451341 | 1.00 | PTPN5 (0.55) | PTPN5CES2CES1PDE2AACP3 | |
| SCHEMBL342466 | 1.00 | PTPN5 (0.55) | PTPN5CES2CES1PDE2AACP3 | |
| SCHEMBL2276065 | 0.94 | PTPN5 (0.64) | PTPN5CES2CES1PDE2AKIF11 | |
| SCHEMBL2276063 | 0.94 | PTPN5 (0.64) | PTPN5CES2CES1PDE2AKIF11 | |
| SCHEMBL2276059 | 0.94 | PTPN5 (0.64) | PTPN5CES2CES1PDE2AKIF11 | |
| SCHEMBL11125737 | 0.88 | PTPN5 (0.46) | PTPN5CES2CES1PDE2AAKR1C3 | |
| SCHEMBL28611305 | 0.85 | TRPV1 (0.49) | PTPN5CES2CES1PDE2A | |
| SCHEMBL30521586 | 0.84 | PTPN5 (0.53) | PTPN5CES2CES1PDE2AHSD11B1 | |
| SCHEMBL18290606 | 0.84 | PTPN5 (0.53) | PTPN5CES2CES1PDE2ANOS3 | |
| SCHEMBL9668161 | 0.82 | PDE2A (0.56) | PTPN5CES2CES1PDE2AACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113584090-B | Biological preparation method of chemokine CCR 5 antagonist AD101 chiral intermediate | 浙江工业大学 | 2024-07-19 | — | — | CN | claimed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3962602-B1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-113584090-B | Biological preparation method of chemokine CCR 5 antagonist AD101 chiral intermediate | 浙江工业大学 | 2024-07-19 | — | — | CN | disclosed |
| CN-113584090-B | Biological preparation method of chemokine CCR 5 antagonist AD101 chiral intermediate | 浙江工业大学 | 2024-07-19 | — | — | CN | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240010606-A1 | FUMARATE DERIVATIVES AND THEIR MEDICAL USE | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-11 | — | — | US | disclosed |
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
| CN-1894213-A | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK & CO INC (CA) | 2007-01-10 | — | — | CN | disclosed |
| EP-1697322-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CYCLOPENTANOINDOLE DERIVATIVES | Merck Frosst Canada Ltd. (CA) | 2006-09-06 | — | — | EP | disclosed |
| US-7019022-B2 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA & CO. (CA) | 2006-03-28 | — | — | US | disclosed |
| EP-1624871-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA LTD. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005056527-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CYCLOPENTANOINDOLE DERIVATIVES | MERCK FROSST CANADA LTD. (CA) | 2005-06-23 | — | — | WO | disclosed |
| WO-2004103370-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | MERCK & CO., INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | PTPN5 2980/4885CES2 1206/4885CES1 200/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | PTPN5 1125/4885CES2 790/4885CES1 640/4885 |
| US-20230399287-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, HLA-DRB1 | PTPN5 2124/4885CES2 3187/4885CES1 570/4885 |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, LIPA, APOB | PTPN5 2022/4885CES2 1521/4885CES1 227/4885 |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | PTGIR, PTGDR, PTGDR2 | PTPN5 4202/4885CES2 3574/4885CES1 3230/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | PTPN5 1849/4885CES2 995/4885CES1 325/4885 |
| US-20240010606-A1 | FUMARATE DERIVATIVES AND THEIR MEDICAL USE | FH, SUCNR1, ARG2 | PTPN5 3653/4885CES2 4024/4885CES1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.